Since SITC published its first CPG for the use of immunotherapy for the treatment of bladder carcinoma in 2017, immunotherapeutic options for the treatment of urothelial cancer have expanded substantially with approvals for checkpoint inhibitors in multiple advanced disease settings and emerging data on adjuvant approaches.
SITC's Urothelial Cancer Immunotherapy Guideline Expert Panel convened to developed and publish an updated CPG, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment or urothelial cancer" on July 15, 2021 in the Journal for Immunotherapy of Cancer (JITC) to help clinicians navigate the evolving therapeutic landscape and ultimately improve outcomes for patients, SITC's panel of experts generated updated and expanded evidence- and consensus-based recommendations on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs) and patient quality of life (QOL) considerations.SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced.
Published July 15, 2021 in the Journal for ImmunoTherapy of Cancer (JITC) as "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer"
*This webinar is supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com